September 26, 2016 — IBA (Ion Beam Applications S.A.) and Philips announced that they are stepping up their combined efforts in adaptive proton therapy planning through a new long-term collaboration agreement.
The collaboration between the two companies includes the joint marketing and sales of Philips’ imaging and clinical informatics solutions in oncology and IBA’s proton therapy solutions, and the joint development of new products for image-guided proton therapy and treatment modalities. IBA and Philips share the understanding that adaptive therapy planning is key to meeting this objective. The strategic partners have already secured certified compatibility between Philips’ Pinnacle3 therapy planning software and IBA’s proton therapy solution, and they will now jointly develop next-generation proton therapy planning methods to further increase efficiencies in the patient treatment workflow.
Also a result of the collaboration, more than 30 IBA proton therapy centers are expected to benefit from an enhanced cone beam computed tomography (CBCT) imaging technology. This advanced imaging technology provides the large field-of-view needed for enhanced image guidance during proton therapy procedures. To this end, a new software algorithm with an optimized balance between speed and image quality has been developed by the two long-term partners.
IBA and Philips are currently installing state-of-the-art proton therapy solutions at three compact proton therapy centers in the United Kingdom, one compact center in the Middle East, and one large proton therapy center in India. Depending on the proton therapy center, the installed solution can include IBA’s proton therapy systems, such as the Proteus One and Proteus Plus, and Philips’ imaging and clinical informatics solutions, such as Philips’ Big Bore CT and positron emission tomography (PET)/CT systems and Philips’ Pinnacle3 Treatment Planning System.
For more information: www.iba-worldwide.com, www.usa.philips.com/healthcare
March 28, 2024 
